These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11168506)

  • 1. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia.
    Tefferi A; Jiménez T; Gray LA; Mesa RA; Chen MG
    Eur J Haematol; 2001 Jan; 66(1):37-42. PubMed ID: 11168506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.
    Elliott MA; Chen MG; Silverstein MN; Tefferi A
    Br J Haematol; 1998 Nov; 103(2):505-11. PubMed ID: 9827926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
    Tefferi A; Mesa RA; Nagorney DM; Schroeder G; Silverstein MN
    Blood; 2000 Apr; 95(7):2226-33. PubMed ID: 10733489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia.
    Tefferi A; Silverstein MN; Li CY
    Br J Haematol; 1997 Nov; 99(2):352-7. PubMed ID: 9375753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases.
    Akpek G; McAneny D; Weintraub L
    J Surg Oncol; 2001 May; 77(1):42-8. PubMed ID: 11344482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated and preemptive palliative radiotherapy of symptomatic hepatomegaly in a patient with advanced myelofibrosis.
    Riesterer O; Gmür J; Lütolf U
    Onkologie; 2008 Jun; 31(6):325-7. PubMed ID: 18547974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
    Faoro LN; Tefferi A; Mesa RA
    Eur J Haematol; 2005 Feb; 74(2):117-20. PubMed ID: 15654901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A
    Semin Oncol; 2005 Aug; 32(4):403-13. PubMed ID: 16202686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative splenectomy in myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A
    Leuk Lymphoma; 2001; 42(5):901-11. PubMed ID: 11697645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.
    Mesa RA; Nagorney DS; Schwager S; Allred J; Tefferi A
    Cancer; 2006 Jul; 107(2):361-70. PubMed ID: 16770787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.
    Barosi G; Ambrosetti A; Buratti A; Finelli C; Liberato NL; Quaglini S; Ricetti MM; Visani G; Tura S; Ascari E
    Leukemia; 1993 Feb; 7(2):200-6. PubMed ID: 8426474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Tefferi A
    Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelofibrosis with myeloid metaplasia. A study of 24 consecutive patients].
    Bettini R; Redaelli S; Marzetta K; Maino C; Sala D; Saccà V; Gorini M
    Recenti Prog Med; 2004; 95(7-8):358-64. PubMed ID: 15303545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
    Firat S; Murray K; Erickson B
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):201-7. PubMed ID: 12909234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.
    Visani G; Finelli C; Castelli U; Petti MC; Ricci P; Vianelli N; Gianni L; Zuffa E; Aloe Spiriti MA; Latagliata R
    Br J Haematol; 1990 May; 75(1):4-9. PubMed ID: 2375922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia.
    Steensma DP; Hook CC; Stafford SL; Tefferi A
    Br J Haematol; 2002 Sep; 118(3):813-6. PubMed ID: 12181050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
    Cervantes F
    Pathol Biol (Paris); 2001 Mar; 49(2):148-52. PubMed ID: 11317960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Schroeder G; Tefferi A
    Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
    Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
    Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
    Mesa RA
    Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.